



## AVAILABILITY OF THE HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2015

**Paris, 29th September 2015** – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a publicly traded, clinical stage biotech company developing and commercializing therapeutic antiviral drugs and vaccines, today announced that the Half-year Financial report (01/01/2015 – 30/06/2015) is now available and has been filed with the Autorité des Marchés Financier (AMF).

The report is available on ABIVAX's website [www.abivax.com](http://www.abivax.com) in the "Investors" section.

### About ABIVAX ([www.abivax.com](http://www.abivax.com))

ABIVAX is an advanced clinical development biotech company focused on becoming a global leader in the discovery, development and commercialization of therapeutic antiviral drugs and vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B.

ABIVAX has 2 compounds in clinical stage development: ABX464 a novel small molecule against HIV with a number of important potential competitive advantages, and ABX203, a therapeutic vaccine candidate that could be a cure for chronic Hepatitis B. The broader ABIVAX portfolio includes additional anti-viral compounds against e.g. Dengue, Chikungunya and Ebola that may enter the clinical stage in the coming 18 months.

ABX464 has been developed using ABIVAX' anti-viral platform that allows the Company to address a broad range of viral targets involved in the production and management of viral RNA within the host cell. ABIVAX also has access to a number of cutting edge technologies including complex molecular protein/RNA-pro interactions to discover and develop proprietary breakthrough therapies to help patients' clear important pathogenic viruses. Headquartered in Paris, France, ABIVAX conducts its research and development in Évry (France) and Montpellier (France). In addition, ABIVAX benefits from long term partnerships with the Cuban Center for Genetic Engineering and Biotechnology (Havana, Cuba), The Finlay Institute (Havana, Cuba), the Molecular Genetics Institute of Montpellier (CNRS-Université de Montpellier, France), the Curie Institute (Paris, France), the Scripps Research Institute (La Jolla, CA, USA), the University of Chicago (Chicago, IL, USA), Brigham Young University (Provo, UT, USA), and the Institut Pasteur (Paris, France). ABIVAX intends to pursue further business development opportunities to access commercial products as part of its overall corporate strategy.

ABIVAX was founded by Dr. Philippe Pouletty, M.D., managing partner at Truffle Capital, the cornerstone investor in ABIVAX since its creation. The company is listed on the regulated market of Euronext Paris, compartment B (ISIN code: FR0012333284 – Ticker: ABVX). For more information, please visit [www.abivax.com](http://www.abivax.com).

Follow us on Twitter @ABIVAX\_

### Contacts

#### Investor relations

Raquel Lizarraga

[raquel.lizarraga@abivax.com](mailto:raquel.lizarraga@abivax.com)

+33 1 53 83 06 93

#### Press relations

ALIZE RP

Caroline Carmagnol / Florence Portejoie

[abivax@alizerp.com](mailto:abivax@alizerp.com)

+33 6 64 18 99 59 / + 33 1 44 54 36 64